» Articles » PMID: 15154850

The CBP/p300 TAZ1 Domain in Its Native State is Not a Binding Partner of MDM2

Overview
Journal Biochem J
Specialty Biochemistry
Date 2004 May 25
PMID 15154850
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The transcriptional co-activator CBP [CREB (cAMP-response-element-binding protein)-binding protein] and its paralogue p300 play a key role in the regulation of both activity and stability of the tumour suppressor p53. Degradation of p53 is mediated by the ubiquitin ligase MDM2 (mouse double minute protein) and is also reported to be regulated by CBP/p300. Direct protein-protein interaction between a central domain of MDM2 and the TAZ1 (transcriptional adaptor zinc-binding domain) [C/H1 (cysteine/histidine-rich region 1)] domain of p300 and subsequent formation of a ternary complex including p53 have been reported previously. We expressed and purified the proposed binding domains of HDM2 (human homologue of MDM2) and CBP, and examined their interactions using CD spectroscopy. The binding studies were extended by using natively purified GST (glutathione S-transferase)-p300 TAZ1 and GST-p53 fusion proteins, together with in vitro translated HDM2 fragments, under similar solution conditions to those in previous studies, but omitting added EDTA, which causes unfolding and aggregation of the zinc-binding TAZ1 domain. Comparing the binding properties of the known TAZ1 interaction partners HIF-1alpha (hypoxia-inducible factor 1), CITED2 (CBP/p300-interacting transactivator with glutamic- and aspartic-rich tail) and STAT2 (signal transducer and activator of transcription 2) with HDM2, our data suggest that TAZ1 in its native state does not serve as a specific recognition domain of HDM2. Rather, unfolded TAZ1 and HDM2 proteins have a high tendency to aggregate, and non-specific protein complexes are formed under certain conditions.

Citing Articles

Cited2 is a key regulator of placental development and plasticity.

Kuna M, Soares M Bioessays. 2024; 46(8):e2300118.

PMID: 38922923 PMC: 11331489. DOI: 10.1002/bies.202300118.


GTSF1 accelerates target RNA cleavage by PIWI-clade Argonaute proteins.

Arif A, Bailey S, Izumi N, Anzelon T, Ozata D, Andersson C Nature. 2022; 608(7923):618-625.

PMID: 35772669 PMC: 9385479. DOI: 10.1038/s41586-022-05009-0.


Pitfalls at Chemistry of Adenoviral Vector Vaccine against COVID-19 and How to Circumvent it.

Ahmed A, Nezami M, Alkattan A Adv Pharm Bull. 2022; 12(2):217-218.

PMID: 35620347 PMC: 9106963. DOI: 10.34172/apb.2022.024.


Role of CITED2 in stem cells and cancer.

An B, Ji X, Gong Y Oncol Lett. 2020; 20(4):107.

PMID: 32831926 PMC: 7439111. DOI: 10.3892/ol.2020.11968.


Transcription factor dimerization activates the p300 acetyltransferase.

Ortega E, Rengachari S, Ibrahim Z, Hoghoughi N, Gaucher J, Holehouse A Nature. 2018; 562(7728):538-544.

PMID: 30323286 PMC: 6914384. DOI: 10.1038/s41586-018-0621-1.


References
1.
Van Orden K, Giebler H, Lemasson I, Gonzales M, Nyborg J . Binding of p53 to the KIX domain of CREB binding protein. A potential link to human T-cell leukemia virus, type I-associated leukemogenesis. J Biol Chem. 1999; 274(37):26321-8. DOI: 10.1074/jbc.274.37.26321. View

2.
Goto N, Zor T, Martinez-Yamout M, Dyson H, Wright P . Cooperativity in transcription factor binding to the coactivator CREB-binding protein (CBP). The mixed lineage leukemia protein (MLL) activation domain binds to an allosteric site on the KIX domain. J Biol Chem. 2002; 277(45):43168-74. DOI: 10.1074/jbc.M207660200. View

3.
Li X, Coffino P . High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol. 1996; 70(7):4509-16. PMC: 190386. DOI: 10.1128/JVI.70.7.4509-4516.1996. View

4.
Zeng X, Chen L, Jost C, Maya R, Keller D, Wang X . MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol. 1999; 19(5):3257-66. PMC: 84120. DOI: 10.1128/MCB.19.5.3257. View

5.
Goodman R, Smolik S . CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000; 14(13):1553-77. View